Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33529
Abstract: The achievement of a 3‐month complete molecular response (CMR) is a major prognostic factor for survival in patients with Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukemia (ALL). However, 25% of patients relapse during therapy with tyrosine… read more here.
Keywords: molecular response; positive acute; patients philadelphia; complete molecular ... See more keywords